| |
|
|
|
EuroSciCon, Cineworld: The O2 Peninsula Square London London SE10 0DX United Kingdom
Wednesday 26th March 2014
This event will look at discovering and producing new antibiotics to combat tuberculosis. The conference will discuss target and compound discovery, new potential anti-TB compounds in development, clinical trial design and early trial results. We invite researchers interested in all aspects of drug development and welcome participants from academia, industry, government and non-governmental organizations. We also welcome abstracts for oral and poster presentation. This event has CPD accreditation and is part of the 2014 TB Summit -www.TBSummit2014.com
Meeting Chair: Dr. Sanjib Bhakta, Director of ISMB-Mycobacteria Research Laboratory and University Senior Lecturer, Institute of Structural and Molecular Biology, Birkbeck, University of London and UCL, UK
The deadline for abstract submissions for oral presentation has now passed. Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors atwww.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf
Talks include
A study in persistence: overcoming the barriers to shorter treatment for pulmonary tuberculosis
Dr Derek Sloan, Senior Clinical Academic in Respiratory Medicine, Liverpool School of Tropical Medicine, Liverpool Heart and Chest Hospital, UK
New treatments to cure drug-susceptible pulmonary tuberculosis in less than 6 months are urgently required. Although novel regimens are being assessed in clinical trials, reliable surrogate biomarkers are needed to predict the eventual outcome of therapy from studies of 2 months duration. Pharmacokinetic-pharmacodynamic (PK-PD) modelling of the early bacillary elimination rate may help generate these biomarkers and accelerate drug development. Additionally, fluorescence microscopy can identify sub-populations of M tuberculosis organisms with heterogeneous lipid metabolism; possibly identifying “persister” cells which are difficult to kill and may be associated with treatment failure or relapse.
Mycobacterium tuberculosis drug discovery using new targets essential for survival inside macrophages
Professor Edith Sim, Professor Emeritus of Pharmacology, University of Oxford, UK
The need for new treatment for tuberculosis is evident from the increase in multi drug resistant TB which is compounded by the long duration of existing drug treatments. The need for a pipeline ofpotential new drugs is related to minimising the subsequent development of strains which are resistant in the future. The difficulty in treating tuberculosis apart from the soioeconomic factrs is the life style of the organism which can survive inside cells. Therefore targetting pathways which are essential for intracellular survival is an important strategy. The work presented in this talk will focus on a group of proteins encoded by a gene cluster which is essential for survival inside macrophage and where gene deletion and chemical inhibition have been demonstrated to have similar effects on the survival of mycobacteria.
How to improve the results of the therapy for urogenital tuberculosis
Professor Ekaterina Kulchavenya, Principal researcher, Head of Urogenital Dpt, Novosibirsk Research TB Institute, Medical University, The Russian Federation
Urogenital Tuberculosis (UGTB) is complicated by bladder tuberculosis (TB) in more than half of cases; late diagnosis and/or absence of pathogenetic therapy leads to the development of shrinked bladder up to full its obliteration. Standard therapy presented poor results: in 57.9% developed complications: posttuberculous cystalgia (36.8%) and microcystis (21.1%). Modified etiopathogenetic therapy, included trospium chloride, increases frequency of recurrence twice and allows avoiding of developing of microcystis at all.
Plant-Derived Compounds a Source of Anti-Mycobacterium Tuberculosis Agents
Dr Maria del Rayo Camacho-Corona, Universidad Autónoma de Nuevo León, Mexico
Clinico-radiological response of TB abscesses in children treated with Thalidomide
Dr Ronald van Toorn, Consultant, Stellenbosch University, South Africa
Tuberculosis abscesses are known to develop or enlarge despite appropriate anti-TB treatment. This phenomenon, the result of immune reconstitution inflammatory syndrome (IRIS), is often more severe in the setting of HIV co-infection and may be life threatening. TB abscesses are notoriously resistant to therapy and require total surgical excision for cure. In our experience, TB abscesses often respond to thalidomide, a potent tumour necrosis alpha-inhibitor. Aim: To describe the clinico-radiological response of TB abscesses in 16 consecutive children treated with thalidomide.
The Management of Tuberculosis in Children by Paediatricians in the Private Sector, in Mumbai, India
Dr. Carolyn Tauro, StopTBIndia, Tata Institute of Social Sciences, India
Among 1.3 million new tuberculosis (TB) cases in India seven percent were children, many of whom seek care outside of the national TB programme. The wide variety of private providers and their practices poses a problem in TB control. This descriptive study involved sixty-four private paediatricians in Mumbai, who prescribe a variety of investigations and drugs in the management of TB and MDRTB drugs. Challenges included issues with cost, compliance, regimens, unpalatable medicines and child unfriendly drug formulations. Increased public-private partnerships, monitored implementation of standard guidelines and practical solutions to tackle these challenges in India need to be sought.
Improving outcome of TB meningitis; intensified antibiotic treatment and better adjuvant therapy
Dr Reinout Van Crevel, MD, PhD, Associate Professor in International Health, Radboud Univeristy Medical Centre Nijmegen, The Netherlands
Intensified antibiotic treatment may improve outcome of TB meningitis. Rifampicin, key to successful treatment of TB meningitis, poorly penetrates the CSF and may be underdosed. Fluoroquinolones may be beneficial because of their high antimycobacterial potency and good CSF penetration. We recently evaluated high-dose rifampicin and moxifloxacin in a phase 2 trial in TB meningitis patients in Indonesia.(1) Immunomodulation may be another way forward. Adjunctive corticosteroids lower mortality, but neurological disability is not affected. Exciting new insights in the role of pro- and anti-inflammatory eicosanoids in TB meningitis may lead to alternative adjunctive treatment for which studies are now being prepared. (1) Ruslami et al, Lancet Infectious Diseases 2013;13:27-35.
Tuberculosis Therapy under anti-TNF agents
Dr Tomoshige Matsumoto, Director of Department of Clinical Laboratory Medicine, Osaka Anti-Tuberculosis Association Osaka Hospital, Japan
Although several TNF inhibitors are used for the treatment of moderate-to-severe active rheumatoid arthritis (RA), a substantial number of serious adverse events occur including reactivation of latent tuberculosis (TB) infection. Currently, the American College of Rheumatology recommends that treatment with biologics can be resumed after completion of the anti-TB treatment, while the British Society of Rheumatology suggests that patients on anti-TNF therapy should receive full anti-tuberculosis chemotherapy, but may continue with anti-TNF therapy if clinically indicated. This discrepancy is due to the limited availability of evidence. We previously reported one successful case in which administration of anti-TB medications followed by re-treatment with infliximab could control RA disease activity without exacerbation of TB. Subsequent studies have also reported favorable outcomes for RA patients with TB treated with re-administration of anti-TNF biologics. We will show our experiences concerning anti-TNF inhibitors and TB therapy, including how to prevent paradoxical response from developing.
Keywords: TB, latent, infection, diagnosis, IGRA,Latent TB; M/XDRTB; genome; proteome; immunome, cell wall, arabinogalactan, drug discovery, benzothiazinone, tuberculosis; treatment; biomarkers; antibiotics, mutation, rpoB, gyrA, gyrB, katG, inhA, Rifampicin resistance, Fluoroquinolone resistance, Isoniazid resistance, Mycobacterium tuberculosis, Thailand, Mangosteen extract, Antimycobacterial activity, air filter, pre-filter, tuberculosis, bladder, complication, urogenital, therapy, TB abscess Thalidomide MRI, TB meningitis; high-dose rifampicin; aspirin; moxifloxacin; eicosanoids, persistence; biomarkers; pharmacokinetics; pharmacodynamics; lipid bodies, anti-TNF agents, biologics, tuberculosis treatment
|
|
|
|
|
|
|
|
Organized by:
|
|
Euroscicon |
|
|
Invited Speakers:
|
|
About the Chair
Sanjib Bhakta is the Director of ISMB-Mycobacteria Research Laboratory at the Institute of Structural and Molecular Biology, Birkbeck, University of London & UCL. His continued research interest (funded by UK-Medical Research Council, Wellcome Trust and EU Research Fund) is focused on developing novel therapeutics to tackle persistence and drug resistance in tuberculosis (XDR-TB, a global health emergency). He has published original research articles for a number of internationally acclaimed journals. Following a BSc (Hons), an MSc and a PhD in Molecular Microbiology & Biochemistry from world class universities and research Institutions in India, Dr Bhakta joined the Oxford University Department of Pharmacology in 2001 as an ISIS innovation Senior Research Scholar and shortly after he was awarded with a Wellcome Trust International Travelling Fellowship. He graduated from The Queen’s College, University of Oxford in 2005 completing a second doctoral degree (DPhil) and received a “Sir William Paton Prize” for the best graduate research presentation in Pharmacology. In 2006 he attained his first academic appointment at Birkbeck, University of London as a University Lecturer to lead his TB drug discovery research and research led teaching on antimicrobials. He became a Fellow of the Higher Education Academy, UK after achieving a post graduate certificate in Teaching and Life Long Learning in Higher Education (PGCHE) from the University of London in 2008. He is a core member of Tuberculosis Drug Discovery-UK, the Institute of Structural and Molecular Biology, NIMR/Birkbeck/UCL and an affiliated academic Fellow of the Centre for Infection, Immunity and Disease mechanism, Brunel University. He is a member of a number of international societies and Editorial Board Member of peer reviewed international journals. Sanjib held Visiting Faculty posts at several recognized universities and research institutes in India and actively engaged as an Honorary Consultant for National TB Research at the Indian Development Foundation. He is a STEM-Ambassador on a UK research council funded project and a “Scientist in Residence” at the St Mary’s School in Buckinghamshire. He was elected as a Fellow of the Royal Society of Medicine in 2008 and recognised as a Chartered Microbiologist in the UK. He hosted World TB Day events at University of London since 2010 and chaired the EuroSciCon conference “Can we beat…Mycobacterium tuberculosis” in 2013.
About the Speakers
Derek Sloan has worked in high and low income countries, accruing extensive experience in the management of tuberculosis and HIV. After spending time in Kenya, South Africa and Malawi he currently lives in Liverpool. He continues to engage in clinical and academic activities with a global perspective and his research has been funded by the Wellcome Trust. His work focusses on the clinical pharmacology of anti-TB drugs, the metabolic behaviour of TB bacilli under drug pressure and PK-PD modeling of patient responses to anti-TB chemotherapy.
Edith Sim studied Biochemistry in Edinburgh and obtained her doctorate in Oxford. She worked in Grenoble on membrane proteins in bacteria as a Royal Society Research Fellow before returning to Oxford as a junior lecturer where she ran a reserach group mainly funded by the Wellcome Trust. She became Head of the Department of Pharmacology has also served as the Director of the Medical Sciences Division Training Group including post-graduate training programmes. She has published extensively on subjects at the interface between chemistry and protein science in the field of tuberculosis. She has supervised many graduate students and one of her students, Anna Upton, is now Director of Reserach at the TB Global Alliance. Edith Sim is a member of the ACid Fast Club and is currently the Dean of the Faculty of Science Engineering and Computing at Kingston University, Kingston-on-Thames where her reserach team are based. She is a Reserach Fellow at St Peter's College Oxford and an honorary member of the Pharmacology Department, Oxford University.
Ekaterina Kulchavenya has completed her PhD at the age of 28 years from Moscow Research TB Institute; from 2002 she is professor. Now she is a principal researcher of Novosibirsk Research TB Institute and professor of Novosibirsk Medical University. She has published more than 55 papers in reputed journals and 8 monographs and she is an author of chapters on urogenital TB in Russian National Guideline on Urology and in International Consultation on Urological Diseases.She is an author of many new patented techniques, allowed significantly improves the therapy for extrapulmonary tuberculosis as well as prostate and bladder diseases.
Tomoshige Matsumoto is a physician, and the Director of the Department of Clinical Diagnositc Laboratory at Osaka Anti-Tuberculosis Association Osaka Hospital, Japan and co-editor in chief of the Journal of Infectious Diseases and Therapeutics. He is as well Advisor for molecular epidemiology of tuberculosis and especially tuberculosis infection under biologics therapy. His education and career have been made in Osaka, Japan. He at first engaged a molecular cloning and characterization of SOCS-1/SSI-1/CIS, negative feed back regulator of cytokin signaling in cells, under the excellent teaching of Dr. Tetsuji Naka and Dr. Tadamitsu Kishimoto. They proposed the existance of negative feed back regulation system in cells (nature) and characterized the SOCS-1 (pnas). Then, his career has been a clinical application of cytokine signaling for various diseases. He has engaged in developing anti-IL6 receptor therapy, biologic therapy, for castleman disease(blood) and rheumatoid arthritis, which is now available as actemura(R). Then his career has been shifted to the infection therapies especially tuberculosis under the biologics. He has firstly showed a successful anti-TNF treatment for rheumatoid arthritis in a patient with tuberculosis(NEJM). He experienced more than 20 anti-TNF therapies in patients with tuberculosis.
Ronald van Toorn is a South African pediatric neurologist wiith an interest in neuroinfectious diseases, especially TB meningitis. The title of his PHD (near completion) is "Childhood tuberculosis meningitis: challenging current management strategies".
Reinout van Crevel, a Dutch infectious disease specialist, has led a patient-oriented research program on TB in Indonesia, integrating basic sciences, clinical research and public health for more than 10 years. He also set up a program on prevention and care of HIV in the context of injecting drug use in Indonesia. These collaborative research acitivities have a strong aspect of academic capacity building and improving patient services. One of his main topics of interests is TB meningitis and pharmacokinetic aspects of TB treatment.
Carolyn Kavita Tauro is the research head and co-founder at Stop TB India (www.stoptbindia.org), a non-governmental organization, which works towards research and advocating in the field of TB. She is pursuing Master of Public Health in Social Epidemiology, at Tata Institute of Social Science in Mumbai, India. Her past work experience includes field medical work with Medecines sans Frontieres (MSF) in conflict areas, managing basic health care, Maternal and Child Health programs and tuberculosis. Later, she was part of the MSF national coordination team involved in projects of Mental Health, Tuberculosis, HIV/AIDS, Maternal and Child health and Malnutrition.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
The deadline for abstract submissions for oral presentation has now passed.
|
|
|
|
|
|
|
|
Registration:
|
|
Registration Website: http://www.regonline.co.uk/TBTreat2014
|
|
|
E-mail:
|
|
enquiries@euroscicon.com
|
|
|
|
|
|
|
|
|